**Latin American Journal of Clinical Sciences and Medical Technology is an open access magazine.

To read all published articles and materials you just need to register

Registration is free of charge.   Register now

If you already have registered please   Log In
**
Latin American Journal of Clinical Sciences and Medical Tecnology
Thursday April 9th, 2020
Mission. To accessibly present interesting topics and original research in clinical sciences by means of procedures and digital technology which are friendly for authors, reviewers, and the reader.
Vision. To create a forum to discuss relevant topics and to spread out the original clinical research produced in Latin America. In that way, we will foster the development of high-quality research and publication in Latin-America in order to make visible the expertise and evidence our clinicians all over the world.
Objective. To be an effective and state-of-the-art tool for spreading Latin American original research with the best visibility, availability, and legibility that will ensure an increase in the number, quality and citation of the Latin American region. Based on that, our journal will contribute to improve the comprehension of basic concepts for the use of the latest diagnosis and treatment resources.
Submit
& Guide
for Authors
Authors
Access
Reviewers
Access
Current
Issue
Previous
Issue
Contact Us
Editorial
Board
Latin American Journal of Clinical Sciences and Medical Technology is an international, Open Access magazine, which quarterly publishes articles in Spanish and in English, and it is spread out online and in printed versions. It is a scientific, academic tool focused on original Latin-American research, as well as on subjects of interest that will undoubtedly enrich the continuing medical education in the aforementioned geographical area.

Pharmacological aspects and clues for the rational use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic

François Noël, François Noël, François Noël, Jaderson Lima

Since there is an urgent need for COVID-19 treatment, the pandemic disease caused by SARS-CoV-2, the repurposing of available drugs is a quick and cheap option, with chloroquine (CQ) and hydroxychloroquine (HCQ) being the most quoted drugs in this context. As a rigorous evaluation of the available data is needed to help to decide on the eventual use of these drugs, the first objective of this work is to critically review the available in vitro assay, clinical studies and putative mechanism(s) of action of CQ/HCQ concerning COVID-19, either alone or in association with azithromycin (AZM). The second objective is to discuss the drug alternatives to treat COVID-19, with emphasis on Brazil, Latin America, and countries where malaria is endemic. Finally, we describe some of the on-going international clinical trials and their therapeutic schemes. We conclude that: 1) there is a good rationale for HCQ use, at least within a compassionate approach, for COVID-19 treatment, possibly at not to severe stage of the disease; 2) the risk/benefit ratio of HCQ use alone or in combination with other drugs such as AZM has yet to be established with the available level of evidence, according to the evidence-based medicine principles.

Learn more

Are the high smoking rates related to COVID-19 outbreaks?

Andres F. Zuluaga, Maria A. Montoya-Giraldo, Jefferson A. Buendia

The ongoing outbreak of coronavirus disease 2019 has become a challenge for researchers and health systems.1 Recently, Cai commented on Lancet Respiratory Medicine that COVID-19 prevalence is dependent, among other variables, on sex and smoking.2 Brake3 demonstrated that smoking upregulates the expression of Angiotensin-Converting Enzyme-2 (ACE2) receptor in type-2 pneumocytes of smokers with COPD, increasing the ability of this coronavirus to infect the human cells. The e-cigarettes and heat-not-burn (HNB) devices (e.g.& JUUL) also have been involved with the ACE2 overexpression and higher prevalence of viral respiratory infections (e.g.& influenza).&

Learn more

Adjustment of Immunosuppression for Liver Transplant Recipients Infected with HCV and Treated with Paritaprevir/Ritonavir-Ombitasvir/Dasabuvir and Ribavirin

Liz Toapanta-Yanchapaxi, Erwin Chiquete, Víctor Manuel Páez-Zayas, Juan Francisco Sánchez-Ávila, Alan G. Contreras-Saldívar, Mario Vilatobá-Chapa, Rodrigo Cruz-Martínez, Rafael Leal-Villalpando, Jorge L. Zamudio-Bautista, Ignacio García-Juárez

Introduction. Eradication rates of hepatitis C virus (HCV) infection is likely to rise after liver transplantation (LT). We aimed to evaluate the clinical role of a simple method for calcineurin inhibitors (CNI) adjustment in post-LT patients receiving paritaprevir/ritonavir/ombitasvir/dasabuvir and ribavirin (3D scheme). Material and methods. We included post-LT adult patients between 2014 and 2017. All selected subjects had at least a 12-month follow-up receiving a stable dose of a CNI. All patients had HCV-1 infection, no liver cirrhosis and received the 3D scheme for 24 weeks. Serial blood concentration measurements of immunosuppressant drugs were obtained. CNI dose was adjusted since 3D scheme initiation and during follow-up until adequate levels were obtained. Results. A total of 10 LT patients (mean age 58.7±11.26 years, 60% women), out of LT 22, received the 3D regime. Tacrolimus was used in 9 patients: four patients received a dose of 0.5 mg every 10 days and 5 received doses of 0.25 mg every 5 days (mean levels, 9.07±5.56 ng/mL). The trough concentration (Ctrough) was 2 ng/mL and the maximum concentration (Cmax) was 30 ng/mL. Only one patient was treated with cyclosporine (mean blood levels of 152.85±54.55 ng/mL). All cases exhibited a sustained viral response. Discussion and conclusions. It is possible to adjust CNI in LT patients under the 3D regime, with high response rates. Low CNI doses are required to avoid toxicity and side effects in HCV patients receiving protease inhibitors.

Learn more

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology, Año 1, No. 1, octubre, 2019 es una publicación mensual editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez, calle San Luis Potosí # 182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.
Contact us   |   Privacy policy   |   Legal Information

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology, Año 1, No. 1, octubre, 2019 es una publicación mensual editada por Vesalio S.C.; http://www.lajclinsci.com/    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez, calle San Luis Potosí # 182-1, Col. Roma, Alcaldía Cuauhtémoc, C.P. 06700, Ciudad de México; teléfono: 55 64 40 41    Fecha de última modificación, 30 de marzo de 2020.